Project description:OSAHS is a complex,synthetical disease that can lead to multiple system and multiple organ damage as the disease progresses.Metabolic syndrome is the most common complication, but the symptoms at different stages of the disease are different.It is known that miRNAs can be stably in the serum and changes during the development of the disease.Therefore, we speculate that serum miRNAs could biomarkers for OSAHS diagnosis and progression judgment. We used microarrays to detail the miRNA expression of simple OSAHS patients, OSAHS patients with hypertension and healthy controls, and screened out the miRNAs that were differentially expressed between the two groups.
Project description:To identify distinctive miRNA signatures in OSAHS with Mets patients from healthy subjects, that could serve as diagnostic biomarkers or describe differential molecular mechanisms with potential therapeutic implications. 5 OSAHS with metabolic syndrome (MetS) patients and 4 Tibetan healthy subjects were selected as the control group from January 2018 to January 2021, who signed an informed, written consent form. All OSAHS Patients diagnosed by Polysomnography (PSG). Patients suffering from other respiratory diseases, or combined with allergic and autoimmune diseases, tumors and other serious systemic serious primary diseases were excluded from this study. Plasma was isolated and frozen at -80 ◦C.